Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Nature medicine - 1 Apr 2004

Torres Vicente E, Wang Xiaofang, Qian Qi, Somlo Stefan, Harris Peter C, Gattone Vincent H

Abstract excerpt

Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzazepines
Share to Cyclic AMP
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Polycystic Kidney, Autosomal Dominant

Source

Identifiers

PMID: 14991049
DOI: 10.1038/nm1004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.PMID 14991049Read ↗

Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions.Semantic proximity Read ↗

Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.Semantic proximity Read ↗

Therapeutic targets for polycystic kidney disease.Semantic proximity Read ↗

Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.Semantic proximity Read ↗

[Inhibitors of intra-cystic secretion: novel therapies in ADPKD (Autosomal Dominant Polycystic Kidney Disease)].Semantic proximity Read ↗

Review of the Use of Animal Models of Human Polycystic Kidney Disease for the Evaluation of Experimental Therapeutic ModalitiesSemantic proximity Read ↗

Therapeutic advances in the treatment of polycystic kidney disease.Semantic proximity Read ↗

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights.Semantic proximity Read ↗

Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney DiseaseSemantic proximity Read ↗

Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signalingSemantic proximity Read ↗

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonistSemantic proximity Read ↗

Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.